Merck Millipore introduces Millipore Express PHF hydrophilic sterilizing-grade filters for fast, efficient and economical buffer filtration
Faster flow rates than most sterilizing-grade filters, reducing footprint.
Merck Millipore hasintroduced Millipore Express PHF (process protection, high-flux) hydrophilic filters for fast, efficient and economical buffer filtration. The single layer, fast-flowing 0.2 µm PES membrane filters provide sterilizing-grade performance and are ideal for buffers, pH adjusters and other process additives and intermediate fluids as well as cleaning fluids. The single-use, gamma ready filters are available in a fully scalable range of sizes from 25 mm to 76.2 cm cartridges.
The filters are designed to offer high-flux performance and improved process economics. Superior process efficiency and economy result from broad chemical compatibility, high flow rates and extended throughput. Offering faster flow rates than most sterilizing-grade filters, Millipore Express filters allow users to accelerate their processes with the same size filter or reduce their process footprint, using a smaller filter.
Millipore Express PHF filters are compatible with a wide range of buffer chemistries including acids and sodium hydroxide across the entire pH range. The filters can withstand multiple steam-in-place or autoclave sterilization cycles.
"Improving process economics is always an imperative for our customers," said Andrew Bulpin, Vice President, Process Solutions, Merck Millipore. "With a fast flowing membrane design, Millipore Express PHF filters can be used to accelerate current processes or run the same process with a smaller filter footprint. And with a comprehensive range of sizes, these filters can support scale up and technology transfer with ease."
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.